Abbie Celniker, Ph.D is the CEO of Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing innovative protein-based therapies. Dr. Celniker has been in the biotechnology and pharmaceutical industry for over 25 years where she has worked in small and mid-sized biotechnology companies as well as mid-sized and large pharmaceutical companies. Prior to Eleven, Abbie was head of Translational Medicine at Alexion Pharmaceuticals by way of the acquisition of Taligen Therapeutics where she was the President and CEO. Prior to joining Taligen, Dr. Celniker was the Global Head of Novartis Biologics where she was responsible for the oversight of the discovery and development of the Novartis biologics pipeline. Dr. Celniker has also been the Global Head of the Program Office for the Novartis Institutes for Biomedical Research (NIBR) where she was responsible for the global integration and oversight of the Novartis Discovery Portfolio. In a previous role at Millennium Pharmaceuticals, Dr. Celniker led the pipeline portfolio review committee and headed Development Project Management and Pharmaceutical Sciences. Prior to Millennium, Dr. Celniker was at Wyeth, where she was assistant vice president for predevelopment and biopharmaceutical core technologies. She has previously held positions at Genetics Institute, Genentech Inc. and the University of Arizona Cancer Center. Dr. Celniker has a bachelor's degree in biology from the University of California at San Diego and earned her Ph.D. in molecular biology at the University of Arizona.